TG THERAPEUTICS, INC. Costs and Expenses, Related Party
TG THERAPEUTICS, INC. (TGTX) reported Costs and Expenses, Related Party of $1.20 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CostsAndExpensesRelatedParty · last filed 2026-02-27
- TG THERAPEUTICS, INC. costs and expenses, related party for the quarter ending 2025-12-31 was $200.00K, a 0.00% change year-over-year.
- TG THERAPEUTICS, INC. costs and expenses, related party for the quarter ending 2025-09-30 was $200.00K, a 0.00% change year-over-year.
- TG THERAPEUTICS, INC. costs and expenses, related party for the quarter ending 2025-06-30 was $500.00K, a 66.67% increase year-over-year.
- TG THERAPEUTICS, INC. costs and expenses, related party for the quarter ending 2025-03-31 was $300.00K, a 50.00% decline year-over-year.
- TG THERAPEUTICS, INC. costs and expenses, related party for fiscal 2025 was $1.20M, a 7.69% decline from fiscal 2024.
- TG THERAPEUTICS, INC. costs and expenses, related party for fiscal 2024 was $1.30M, a 44.44% increase from fiscal 2023.
- TG THERAPEUTICS, INC. costs and expenses, related party for fiscal 2023 was $900.00K, a 30.77% decline from fiscal 2022.
- TG THERAPEUTICS, INC. costs and expenses, related party for fiscal 2022 was $1.30M, a 44.44% increase from fiscal 2021.
| Period end | Costs and Expenses, Related Party 3 month | Costs and Expenses, Related Party 6 month | Costs and Expenses, Related Party 9 month | Costs and Expenses, Related Party 12 month |
|---|---|---|---|---|
| 2025-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $400.00K derived: sum of 2 quarters · filed 2026-02-27 | $900.00K derived: sum of 3 quarters · filed 2026-02-27 | $1.20M 10-K · filed 2026-02-27 |
| 2025-09-30 | $200.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $700.00K derived: sum of 2 quarters · filed 2025-11-05 | $1.00M 10-Q · filed 2025-11-05 | $1.20M derived: sum of 4 quarters · filed 2026-02-27 |
| 2025-06-30 | $500.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $800.00K 10-Q · filed 2025-08-08 | $1.00M derived: sum of 3 quarters · filed 2026-02-27 | $1.20M derived: sum of 4 quarters · filed 2026-02-27 |
| 2025-03-31 | $300.00K 10-Q · filed 2025-05-09 | $500.00K derived: sum of 2 quarters · filed 2026-02-27 | $700.00K derived: sum of 3 quarters · filed 2026-02-27 | $1.00M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $400.00K derived: sum of 2 quarters · filed 2026-02-27 | $700.00K derived: sum of 3 quarters · filed 2026-02-27 | $1.30M 10-K · filed 2026-02-27 |
| 2024-09-30 | $200.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $500.00K derived: sum of 2 quarters · filed 2025-11-05 | $1.10M 10-Q · filed 2025-11-05 | $1.30M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $300.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $900.00K 10-Q · filed 2025-08-08 | $1.10M derived: sum of 3 quarters · filed 2026-02-27 | $1.30M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $600.00K 10-Q · filed 2025-05-09 | $800.00K derived: sum of 2 quarters · filed 2026-02-27 | $1.00M derived: sum of 3 quarters · filed 2026-02-27 | $1.30M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $400.00K derived: sum of 2 quarters · filed 2026-02-27 | $700.00K derived: sum of 3 quarters · filed 2026-02-27 | $900.00K 10-K · filed 2026-02-27 |
| 2023-09-30 | $200.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $500.00K derived: sum of 2 quarters · filed 2024-11-07 | $700.00K 10-Q · filed 2024-11-07 | $1.40M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $300.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $500.00K 10-Q · filed 2024-08-09 | $1.20M derived: sum of 3 quarters · filed 2025-03-03 | |
| 2023-03-31 | $200.00K 10-Q · filed 2024-05-06 | $900.00K derived: sum of 2 quarters · filed 2025-03-03 | ||
| 2022-12-31 | $700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $1.30M 10-K · filed 2025-03-03 | ||
| 2022-09-30 | $600.00K 10-Q · filed 2023-11-06 | |||
| 2021-12-31 | $900.00K 10-K · filed 2024-02-29 | |||
| 2018-09-30 | $100.00K 10-Q · filed 2019-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |